AiTan (rivoceranib)

News alerts, weekly reports and conference planners

Company:

Advenchen, Bukwang Pharma, HLB Bio Group, Jiangsu Hengrui Pharma

Drug class:

VEGFR-2 inhibitor

Related drugs:

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	rivoceranib Sensitive: B - Late Trials rivoceranib Sensitive : B	rivoceranib Sensitive: B - Late Trials rivoceranib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
TP53 exon 8 mutation	Non Small Cell Lung Cancer	TP53 exon 8 mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
BRCA mutation	HER2 Negative Breast Cancer	BRCA mutation	HER2 Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3
HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + rivoceranib Sensitive: C3 – Early Trials osimertinib + rivoceranib Sensitive : C3	osimertinib + rivoceranib Sensitive: C3 – Early Trials osimertinib + rivoceranib Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + rivoceranib Sensitive: C3 – Early Trials trastuzumab + rivoceranib Sensitive : C3	trastuzumab + rivoceranib Sensitive: C3 – Early Trials trastuzumab + rivoceranib Sensitive : C3

AiTan (rivoceranib)

Associations
(82)

Associations
(82)

AiTan (rivoceranib)

Associations(82)

Associations(82)

Associations
(82)

Associations
(82)